GENEDX HOLDINGS CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.86 USD | +3.04% |
|
+2.18% | +624.55% |
| 04-30 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
| 04-30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 20,163 | 1,076 | 102 | 71.18 | 503.9 | - | - |
| Enterprise Value (EV) 1 | 20,163 | 1,076 | -15.65 | -6.278 | 503.9 | 503.9 | 503.9 |
| P/E ratio | -2.94 x | -1.96 x | -0.16 x | -0.38 x | -6.71 x | -12.3 x | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 5.07 x | 0.43 x | 0.35 x | 2.08 x | 1.84 x | 1.54 x |
| EV / Revenue | - | 5.07 x | 0.43 x | 0.35 x | 2.08 x | 1.84 x | 1.54 x |
| EV / EBITDA | - | -5.39 x | -0.38 x | -0.75 x | -23.6 x | 63.6 x | 10.2 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 55,344 | 7,311 | 11,721 | 25,884 | 26,151 | - | - |
| Reference price 2 | 364.3 | 147.2 | 8.705 | 2.750 | 19.27 | 19.27 | 19.27 |
| Announcement Date | 06/05/21 | 14/03/22 | 14/03/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 212.2 | 234.7 | 202.6 | 242.7 | 273.5 | 327.1 |
| EBITDA 1 | - | -199.6 | -266.7 | -94.56 | -21.35 | 7.924 | 49.24 |
| EBIT 1 | - | -221.4 | -326 | -128.3 | -30.36 | -8.249 | 29.06 |
| Operating Margin | - | -104.34% | -138.93% | -63.34% | -12.51% | -3.02% | 8.88% |
| Earnings before Tax (EBT) | - | -245.4 | -598 | - | - | - | - |
| Net income 1 | -39,908 | -245.4 | -549 | -175.8 | -77.3 | -46.8 | - |
| Net margin | - | -115.64% | -233.91% | -86.77% | -31.85% | -17.11% | - |
| EPS 2 | -123.8 | -74.91 | -53.79 | -7.230 | -2.870 | -1.570 | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 06/05/21 | 14/03/22 | 14/03/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 57.8 | 53.94 | 36.17 | 83.23 | 61.35 | 43.14 | 48.71 | 53.3 | 57.42 | 62.42 | 59.35 | 59.75 | 61.8 | 60.22 | 66.92 |
| EBITDA 1 | -73.02 | -58.88 | -115 | -70.05 | -38.7 | -40.22 | -43.12 | -22.38 | -11.11 | -2.772 | -7 | -5.8 | -3.8 | -2.45 | 0.65 |
| EBIT 1 | -78.81 | -64.68 | -121.7 | -77.04 | -72.74 | -48.86 | -51.62 | -31.05 | -17.2 | -8.02 | -7.888 | -7.796 | -6.318 | -5 | -5.5 |
| Operating Margin | -136.35% | -119.91% | -336.37% | -92.56% | -118.57% | -113.26% | -105.99% | -58.25% | -29.96% | -12.85% | -13.29% | -13.05% | -10.22% | -8.3% | -8.22% |
| Earnings before Tax (EBT) | -40.18 | -76.9 | -134.8 | -77.65 | -308.7 | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | -40.18 | -76.9 | -85.74 | -77.58 | -308.8 | -60.99 | -46.72 | -42.29 | -25.77 | -20.24 | -19.6 | -19 | -17.6 | -16.8 | -10.7 |
| Net margin | -69.52% | -142.56% | -237.06% | -93.21% | -503.28% | -141.38% | -95.92% | -79.33% | -44.89% | -32.42% | -33.02% | -31.8% | -28.48% | -27.9% | -15.99% |
| EPS 2 | -5.610 | -10.23 | -8.250 | -6.600 | -29.04 | -3.040 | -1.840 | -1.640 | -0.9200 | -0.7800 | -0.7400 | -0.6900 | -0.6300 | -0.5800 | -0.3600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 14/03/22 | 12/05/22 | 15/08/22 | 14/11/22 | 14/03/23 | 09/05/23 | 08/08/23 | 30/10/23 | 20/02/24 | 29/04/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | 118 | 77.5 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 9.4 | - | - | - | - | - |
| Capex / Sales | - | 4.43% | - | - | - | - | - |
| Announcement Date | 06/05/21 | 14/03/22 | 14/03/23 | 20/02/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
19.27
USD
Average target price
15.25
USD
Spread / Average Target
-20.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +624.55% | 504M | |
| -17.08% | 8.39B | |
| +53.29% | 3.74B | |
| -37.54% | 2.55B | |
| -9.63% | 2.48B | |
| -13.43% | 2.32B | |
| -5.32% | 1.93B | |
| -18.24% | 1.6B | |
| -36.41% | 1.28B | |
| +2.19% | 1.08B |
- Stock Market
- Equities
- WGS Stock
- Financials GeneDx Holdings Corp.
